Evidence map›Paper›PMID 40836023›Full record

GuidelineEuropean journal of human genetics : EJHG2026

EMQN best practice guidelines for analysis and reporting of microsatellite instability in solid tumours.

Richard Gallon, Liam McCormick, Angelica Saetta, Cristina Albuquerque, Samantha Butler, Treena Cranston, Joanne Field, Ciaron McAnulty, Patrícia Silva, Melanie Cheetham and 2 more

Abstract readPractice Guideline
In one paragraph

Guideline in European journal of human genetics : EJHG, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. New year, new insights in genomic medicine.European journal of human genetics : EJHG · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Richard Gallon *Translational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, UK. richard.gallon@newcastle.ac.uk.ORCID 0000-0002-5395-0099
Liam McCormickGenomic Diagnostics Laboratory, Manchester Centre for Genomic Medicine, St Mary's Hospital, Manchester, UK.ORCID 0000-0001-9557-9403
Angelica Saetta1st Department of Pathology, Faculty of Medicine, National and Kapodistrian University of Athens, Athens, Greece.ORCID 0000-0002-4862-3413
Cristina AlbuquerqueUnidade de Investigação em Patobiologia Molecular, Instituto Português de Oncologia de Lisboa Francisco Gentil, E.P.E., Lisboa, Portugal.ORCID 0000-0002-9707-0317
Samantha ButlerWest Midlands Regional Genetics Laboratory, Birmingham Women's Hospital, Birmingham, UK.
Treena CranstonOxford Medical Genetics Laboratories, Oxford University Hospitals NHS Trust, Oxford, UK.
Joanne FieldEast Midlands Regional Molecular Genetics Service, City Hospital Campus, Nottingham University Hospitals NHS Trust, Nottingham, UK.
Ciaron McAnultyNorthern Genetics Service, The Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK.
Patrícia SilvaUnidade de Investigação em Patobiologia Molecular, Instituto Português de Oncologia de Lisboa Francisco Gentil, E.P.E., Lisboa, Portugal.ORCID 0000-0002-3713-8770
Melanie CheethamEMQN, Manchester, UK.
Katie SheilsEMQN, Manchester, UK. katie.sheils@emqn.org.ORCID 0000-0002-1649-1495
George J Burghel *Genomic Diagnostics Laboratory, Manchester Centre for Genomic Medicine, St Mary's Hospital, Manchester, UK. george.burghel@mft.nhs.uk.ORCID 0000-0001-9360-8194

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Microsatellite instability (MSI) is the accumulation of insertion and deletion variants (instability) in short tandem repeat DNA sequences (microsatellites). High levels of MSI occur following loss of function of the DNA mismatch repair system (MMR). MMR deficiency is an increasingly important cancer biomarker that is associated with chemotherapy resistance and response to immune checkpoint blockade, as well as one of the commonest hereditary cancer syndromes, Lynch syndrome. Since its discovery over two decades ago, our biological understanding, the testing methods, and the clinical implications of MSI analysis have expanded rapidly and up-to-date best practice guidelines are needed. An expert working group reviewed the literature and devised 15 best practice recommendations that were finalised following consultation with clinical and laboratory scientists partnered with EMQN. These include seven recommendations on key technical aspects of MSI testing and eight recommendations on the clinical interpretation and reporting of results. The latter focuses on Lynch syndrome screening and immune checkpoint blockade therapy. Example report wording is provided to assist implementation and standardisation. Common terminology and MSI analysis methods are also discussed. These guidelines are aimed primarily at genomic scientists working in diagnostic testing laboratories, but will provide a useful review of MSI for clinicians, academics, and other related professionals.

Indexed as

Genetic TestingMicrosatellite InstabilityNeoplasmsColorectal Neoplasms, Hereditary NonpolyposisDNA Mismatch RepairHumans

Identifiers

PMID40836023
PMCPMC12816731

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.